Drugs / Triazolam
Triazolam
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | HALCION | — | 1982-11-15 | fda.gov ↗ |
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06837142 | Mar → Apr 2025 | — | Taisho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00058955 | Aug 2003 → Mar 2005 | substance abuse | Orphan Medical | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00671632 | Jun → Dec 2003 | substance abuse | Takeda | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04346095 | Jun → Oct 2020 | lens disorder, macular holes, preretinal fibrosis, retinal detachment +1 | Rocky Vista University, LLC | Unknown | No outcome recorded |
| Phase 4 | NCT03246724 | Oct 2017 → Nov 2019 | — | Boston Medical Center | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03954483 | Oct 2023 → Oct 2026 expected | anxiety disorder | University of Manitoba | Recruiting | No outcome recorded |
| — | NCT02822937 | Jul → Nov 2016 | — | Akili Interactive Labs, Inc. | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1 | NCT02033707 Background | Apr 2014 → Feb 2019 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 1 | NCT01780259 Background | Dec 2012 → May 2013 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT00894699 Comparator | Jun → Sep 2009 | anxiety | Talphera, Inc | Completed | No outcome recorded |
| Phase 2 | NCT00218166 Comparator | Aug 2001 → May 2005 | cocaine abuse | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| Phase 3 | NCT01888497 Comparator | Jul → Dec 2013 | — | Viatris Inc. | Completed | Missed primary |
| — | NCT03360123 Comparator | Jan → Apr 2018 | — | University of Pittsburgh | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-12-30 | Zydus Lifesciences Limited | Zydus receives final approval from the USFDA for Triazolam Tablets zyduslife.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triazolam | “The participants will receive oral triazolam with topical proparacaine and sub-tenon's mixture of lidocaine and marcaine.” NCT04346095 ↗13“Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem” NCT02033707 ↗ “Triazolam, tiagabine, baclofen” NCT00218166 ↗ |
| Known as | Halcion | ChEMBL registry synonym — accepted as the source's own label CHEMBL646 ↗ |
| Known as | Kention | ChEMBL registry synonym — accepted as the source's own label CHEMBL646 ↗ |
| Known as | N05CD05 | ChEMBL registry synonym — accepted as the source's own label CHEMBL646 ↗ |
| Known as | Triazolam civ | ChEMBL registry synonym — accepted as the source's own label CHEMBL646 ↗ |
| Known as | U-33,030 | ChEMBL registry synonym — accepted as the source's own label CHEMBL646 ↗ |
| Modality | Small molecule | “The medications are both benzodiazepines that have similar risks” NCT03360123 ↗ |
| Route | Oral | “Triazolam 0.25 mg, capsules, orally, one day only” NCT00671632 ↗ |